Paola Zaratin

Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Maria Pia Sormani, Nicola De Rossi, Irene Schiavetti et al. · Annals of Neurology · 2021 · 458 citations · Full text

Interference with Heparin Binding and Oligomerization Creates a Novel Anti-Inflammatory Strategy Targeting the Chemokine System

Zoë Johnson, Marie Kosco‐Vilbois, Suzanne Herren et al. · The Journal of Immunology · 2004 · 155 citations · Full text

Heparin Binding, Chemokine Biology, Immunology +23

Modification of Nociception and Morphine Tolerance by the Selective Opiate Receptor-Like Orphan Receptor Antagonist (–)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5 H-benzocyclohepten-5-ol (SB-612111)

Paola Zaratin, Giuseppe Petrone, M. Sbacchi et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 147 citations

In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties

Tiziana Adage, Anne‐Cécile Trillat, Anna Quattropani et al. · European Neuropsychopharmacology · 2007 · 117 citations

Inhibitory Activity, Biochemistry, Medicine +8

Unmet Needs of People with Severe Multiple Sclerosis and Their Carers: Qualitative Findings for a Home-Based Intervention

Claudia Borreani, Elisabetta Bianchi, Erika Pietrolongo et al. · PLoS ONE · 2014 · 95 citations · Full text